A practical reference on melanocortin system: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-06. Anything still debated is marked as such rather than presented as settled.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R agonist | Subtype most often linked to behavioural effects |
| Other reported targets | MC1R, MC3R, MC5R | Activity is not selective for a single subtype |
| Endogenous ligand class | Melanocortin peptides | Alpha-MSH and ACTH act on the same family |
| Peptide architecture | Cyclic heptapeptide | Lactam bridge between the aspartate and lysine residues |
| Central action | Inferred from animal models | Not directly measured in the human brain |
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
The efficacy of cryoneurolysis procedures for pain relief depend on the proximity of the probe to the targeted nerve, surface area of tissue covered by the probe, the rate and duration of cold treatment, and the temperature applied. These variables likely contributed during a trial by Nygaard et al. observing the efficacy of cryoprobe based cryoneuolysis. The group concluded that "when viewed across all assessed timepoints, the results indicate that cryoneurolysis has no meaningful, robust benefit over sham for chronic knee pain."
== External links == Countercurrent multiplier animation from Colorado University. Research about elephant seals using countercurrent heat exchange to keep heat from leaving their body while breathing out, during hibernation. Patent for a snow mask with a removable countercurrent exchange module which keeps the warmth from leaving the mask when breathing out.
Meyer (1940), composer, author, philosopher known for his contributions to the aesthetic theory of music Orrin Keepnews (1943), jazz record producer and winner of the 1988 Grammy Award for Best Album Notes and Best Historical Album Mort Lindsey (1944), musical director for Judy Garland and Merv Griffin Dick Hyman (1948), musical director for Arthur Godfrey; composer or arranger for Hannah and Her Sisters and The Purple Rose of Cairo; Emmy Award winner Philip Springer (1950), composer known for writing the song "Santa Baby" Randy Starr (1951), dentist and composer for Elvis Presley Eric Salzman (1954), composer, producer, critic; founder of the American Music Theater Festival and composer-in-residence of the Center for Contemporary Opera Malcolm Frager (1955), piano virtuoso Mike Berniker (1957), musical producer and winner of nine Grammy Awards Billy Goldenberg (1957), composer and winner of four Emmy Awards John Corigliano (1959), winner of the Pulitzer Prize for Music and Academy Award for Best Original Score Edward Kleban (1959), lyricist for A Chorus Line David Bromberg* (1960s), Grammy Award-nominated musician Art Rosenbaum (1960), Grammy Award-winning art professor and musician at Georgia State University Charles Wuorinen (1961), serialist composer and winner of the Pulitzer Prize for Music for Time's Encomium Charlie Morrow (1962), sound artist and musician Joel Krosnick (1963), chamber musician and member of the Juilliard String Quartet David Rubinson (1963), record and music producer of Apocalypse Now, founder of San Francisco Records and The Automatt recording studio Art Garfunkel (1965), singer of Simon and Garfunkel, famous for the song "The Sound of Silence" Daniel Waitzman (1965), flutist and composer Kenneth Ascher (1966), Academy Award-nominated jazz pianist; writer of "Rainbow Connection" from The Muppet Movie David Schiff (1967), composer Tom Werman (1967), former record producer for Epic Records Billy Cross (1968), guitarist, singer, and producer who lives in Denmark Jon Bauman (1969), "Bowzer" of Sha Na Na James "Plunky" Branch (1969), jazz musician Cameron Brown (1969), jazz bassist Emanuel Ax (1970), concert pianist Marc Copland (1970), jazz pianist and composer Scott Simon (1970), member of Sha Na Na Frederick "Dennis" Greene (1971), member of Sha Na Na; professor of law at the University of Dayton Armen Donelian (1972), jazz pianist Jocko Marcellino (1972), member of Sha Na Na Phil Schaap (1973), Charlie Parker authority and multiple Grammy Award winner for engineering, production, and album notes Eugene Drucker (1973), Grammy Award-winning violinist, member of the Emerson String Quartet Sam Morrison (1973), saxophonist Michael Jeffrey Shapiro (1973), composer and conductor Richard Einhorn (1975), composer, Voices of Light Phil Kline (1975), composer Paul Phillips (1978), conductor, composer, and music scholar at Brown University Erik Friedlander (1982), cellist, son of American photographer Lee Friedlander Robbie Fulks* (1984), Grammy Award-nominated American alternative country singer-songwriter Dave Nachmanoff (1986), award-winning folk singer and sideman to Al Stewart John Bohlinger (1988), musician and music director on NBC program Nashville Star Laura Cantrell (1989), country musician Peter J. Nash (1989), member of 3rd Bass Mac McCaughan (1990), member of indie rockband Superchunk and founder of Merge Records Richard Carrick (1993), pianist, composer, professor at Berklee College of Music Gil Shaham (1993), violinist Jefferson Friedman (1996), composer Tom Kitt (1996), composer, co-winner of the 2010 Pulitzer Prize for Drama and the Tony Award for Best Original Score for his score of the musical Next to Normal R. Luke DuBois (1997), composer and artist Lauryn Hill* (1997), Grammy Award-winning R&B singer and songwriter, and member of The Fugees Sean Lennon* (1997), singer and songwriter, and son of John Lennon and Yoko Ono Orli Shaham (1997), pianist Yelena Dudochkin (1998), Ukrainian-American soprano Scott Hoffman (1999), known by the stage name Babydaddy, member of the rock band Scissor Sisters The Two Man Gentlemen Band, modern musical duo that consists of Fuller Condon (2000) and Andy Bean (2001) Mason Bates (2000), Grammy Award-winning composer Tom Frank (2000), journalist, former member of indie-rock band Jonathan Fire*Eater Hikaru Utada* (2000), Japanese pop star Alicia Keys* (2001), Grammy Award-winning R&B singer and songwriter Brian Weitz (2001), founding member of experimental band Animal Collective Emily and Julia Bruskin (2002), members of the Claremont Trio Ken-David Masur (2002), musical director of the Milwaukee Symphony Orchestra, son of conductor Kurt Masur Ariana Ghez (2003), oboist Nico Muhly (2003), contemporary classical music composer Anna Bulbrook (2004), violinist formerly member of indie band The Airborne Toxic Event Alisa Weilerstein (2004), cellist and 2011 MacArthur Fellow Tristan Perich (2004), contemporary composer and sound artist Peter Cincotti (2005), pianist Ellen Reid (2005), composer and recipient of the 2019 Pulitzer Prize for Music Patrick Higgins (2006), composer, musician, producer Michael Barimo (2006), pop singer and whistler Rostam Batmanglij (2006), member of alt-rock band Vampire Weekend Ezra Koenig (2006), member of alt-rock band Vampire Weekend Chris Tomson (2006), member of alt-rock band Vampire Weekend Chris Baio (2007), member of alt-rock band Vampire Weekend Call Me Ace or Anthony Patterson (2011), rapper Adam Met (2013), member of pop band AJR Danny Mercer (2013), singer, songwriter and producer Nathan Chan (2014), cellist Conrad Tao (2015), composer, pianist, violinist Jack Met* (2019), member of pop band AJR Maude Latour (2022), singer-songwriter Annie Moon (2026), member of a co-ed K-Pop Group ALLDAY PROJECT
The Red Book, formally titled Nomenclature of Inorganic Chemistry, is a collection of recommendations on inorganic chemical nomenclature. It is published at irregular intervals, with the latest full edition published in 2005, in both paper and electronic versions.
=== Available forms === Each Contrave tablet contains 8 mg naltrexone and 90 mg bupropion. Once full dosing is reached (after 4 weeks of administration), the total dosage of Contrave for treating overweight or obesity is two tablets twice daily or 32 mg naltrexone and 360 mg bupropion per day.
Sources: en.wikipedia.org
== Factors that affect distribution == There are many factors that affect a drug's distribution throughout an organism, but Pascuzzo considers that the most important ones are the following: an organism's physical volume, the removal rate and the degree to which a drug binds with plasma proteins and / or tissues.
=== Testing on children in New York City === The New York Psychiatric Institute, associated with Columbia University, the Research Foundation of the City University of New York, and Mount Sinai Medical Center tested fenfluramine intravenously on more than 100 Black and Hispanic boys between the ages of 6 and 10, with delinquent older brothers, to test the theory that delinquent behavior could be predicted by serotonin levels. These studies were conducted before the drug was pulled from the market in September 1997. In 1998, CNN reported that these organizations were under "evaluation" by the Office for Protection from Research Risks, an arm of the National Institutes of Health. An article in Nature reports that these tests were published as a study in Archives of General Psychiatry in 1997 and that "The New York trial, funded largely by the Lowenstein Foundation, with some support from the National Institute of Mental Health, was halted in 1995, two years before the drug was withdrawn." In 1999, The New York Times reported that the Mount Sinai School of Medicine and the Research Foundation of the City University of New York were officially faulted by federal research-ethics officials for conducting these tests. The article reports that the yearlong investigation found no misconduct by the New York State Psychiatric Institute for these tests. This article reports the number of children involved in the study as 150 and states that none were harmed.
Modern columns have different polarity depending on the ligand bonded to the stationary phase. PFP is pentafluorophenyl. CN is cyano. NH2 is amino. ODS is octadecyl or C18. ODCN is a mixed mode column consisting of C18 and nitrile.
=== Comparison of AAS === AAS differ in a variety of ways including in their capacities to be metabolized by steroidogenic enzymes such as 5α-reductase, 3-hydroxysteroid dehydrogenases, and aromatase, in whether their potency as AR agonists is potentiated or diminished by 5α-reduction, in their ratios of anabolic/myotrophic to androgenic effect, in their estrogenic, progestogenic, and neurosteroid activities, in their oral activity, and in their capacity to produce hepatotoxicity.
== Annual Conference == Every year the Association of Biomolecular Resource Facilities annual conference is held during the spring in a varying North American city. This international conference is used to expose members to new and emerging biotechnology through lectures, roundtables, Research Group presentations, poster sessions, workshops and technical exhibits.
Sources: en.wikipedia.org
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.
It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.
Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.